Turgut Bora Cengiz

Dr. Turgut Bora Cengiz

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2024 in Journal of Imaging
Verified
Journal Article
Open access
PDF file
KMKathleen H. Miao
Kathleen H. Miao
JMJulia H. Miao
Julia H. Miao
PBPuneet Belani
Puneet Belani
EDEtan Dayan
Etan Dayan
TCTimothy Carlon
Timothy Carlon
MFMark Finkelstein
Mark Finkelstein
Vertebral compression fractures (VCFs) affect 1.4 million patients every year, especially among the globally aging population, leading to increased morbidity and mortality. Often characterized with symptoms of sudden onset back pain, decreased vertebral height, progressive kyphosis, and limited mobility, VCFs can significantly impact a patient’s quality of life and are a significant public health concern. Imaging modalities in radiology, including radiographs, computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) studies and bone scans, play crucial and evolving roles in the diagnosis, assessment, and management of VCFs. An understanding of anatomy, and the extent to which each imaging modality serves to elucidate that anatomy, is crucial in understanding and providing guidance on fracture severity, classification, associated soft tissue injuries, underlying pathologies, and bone mineral density, ultimately guiding treatment decisions, monitoring treatment response, and predicting prognosis and long-term outcomes. This article thus explores the important role of radiology in illuminating the underlying anatomy and pathophysiology, classification, diagnosis, treatment, and management of patients with VCFs. Continued research and advancements in imaging technologies will further enhance our understanding of VCFs and pave the way for personalized and effective management strategies.

28 September 2018 in Turkish Journal of Surgery
Verified
Journal Article
Open access
DADeniz Atasoy
Deniz Atasoy
AAAfag Aghayeva
Afag Aghayeva
ISIpek Sapci
Ipek Sapci
OBOnur Bayraktar
Onur Bayraktar
TCTurgut Bora Cengiz
Turgut Bora Cengiz
BBBilgi Baca
Bilgi Baca
With increased experience and technological advancement, laparoscopic cholecystectomy is reported to be safe and feasible even in the presence of most of the previously recognized contraindications. The purpose of this study was to explore the effects of prior upper and lower abdominal surgery on laparoscopic cholecystectomy. A retrospective evaluation of all sequential patients who underwent laparoscopic cholecystectomy from January 2014 to June 2016 was conducted. Patients were divided into three groups (Group A: patients without any prior abdominal surgical procedures; Group B: patients with prior upper abdominal surgical procedures; and Group C: patients with prior lower abdominal surgical procedures). A total of 329 patients were assessed. Group A consisted of 223, Group B of 18, and Group C of 88 patients. A statistically significantly higher operative time, postoperative pain, and complication rate after laparoscopic cholecystectomy were noted in patients with prior upper abdominal surgery. The groups were comparable regarding patients' demographics and surgery indications. The length of hospital stay was not statistically different between the groups (p=0.065). According to the results of the current study, prior upper abdominal surgery leads to a significantly longer procedure time, higher postoperative pain, and complication rates after laparoscopic cholecystectomy. However, the length of hospital stay was not affected by the parameters investigated.

10 August 2020 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
TAToms Augustin
Toms Augustin
MMMaitham A. Moslim
Maitham A. Moslim
TCTurgut Bora Cengiz
Turgut Bora Cengiz
KEKevin El‐Hayek
Kevin El‐Hayek
RSRobert Simon
Robert Simon
RWRichard Matthew Walsh
Richard Matthew Walsh

16 May 2024 in Urologia Journal
Verified
Journal Article
Closed access
TCTurgut Bora Cengiz
Turgut Bora Cengiz
RKRaksha Kulkarni
Raksha Kulkarni
MNMatteo Novello
Matteo Novello
AHAnthony Hafez
Anthony Hafez
SGSomali Gavane
Somali Gavane
NGNasrin Ghesani
Nasrin Ghesani
Background: Enzalutamide is an antiandrogen drug used prior to lutetium-177 prostate specific membrane antigen (Lu-PSMA) radioligand therapy and has shown promising results for upregulating the PSMA expression on prostate cancer cells. In this study, we aim to compare prostate specific antigen (PSA) level changes in prostate cancer patients who received enzalutamide to those who did not. Methods: Prostate cancer patients who underwent Lu-PSMA between 2021 and 2023 were retrospectively included. Patients were grouped based on prior enzalutamide therapy: those who received enzalutamide (EZ+) for at least 14 days and those who did not (EZ−). PSA changes and F-18 DCFPyL SUV (Standardized Uptake Values) were compared. Results: Thirty-seven patients were included, 18 EZ+ and 19 EZ−. The median age, Gleason score, and prior chemo/hormonal therapies were similar for EZ+ and EZ−, except for radium-223. Eleven patients (61%) in EZ+ and 13 patients (68%) in EZ− showed a decrease in PSA after the first cycle ( p = 0.64). Four patients (22%) in EZ+ and seven patients (37%) in EZ− had more than 50% decrease in PSA after the first cycle ( p = 0.33). The average percent decline at the end of the treatment was 23.3% in EZ+ and 50.4% in EZ− ( p = 0.4). There was no difference in terms of lesion with highest SUVmax, mean SUV, total tumor volume or activity on pre-therapy PSMA imaging. Conclusion: Enzalutamide treatment prior to Lu-PSMA does not improve patient outcomes when applied remotely. Larger studies evaluating the combination therapies and the timing of enzalutamide are needed to assess its correlation with Lu-PSMA outcomes.

2 August 2017 in Colorectal Disease
Verified
Journal Article
Closed access
PDF file
TCTurgut Bora Cengiz
Turgut Bora Cengiz
AAA. Aghayeva
A. Aghayeva
DAD. Atasoy
D. Atasoy
ISI. Sapci
I. Sapci
OBO. Bayraktar
O. Bayraktar
BBB. Baca
B. Baca

16 May 2023 in Annals of Thoracic Medicine
Verified
Journal Article
Open access
TCTurgut Bora Cengiz
Turgut Bora Cengiz
AAAhmed Abdelrahman
Ahmed Abdelrahman
SRScott A. Rohren
Scott A. Rohren
JDJohn Doucette
John Doucette
MGMunir Ghesani
Munir Ghesani
INTRODUCTION: There is a paucity of data in the literature regarding the diagnostic accuracy of perfusion (Q)-only studies in the absence of ventilation images. This study aims to assess the diagnostic accuracy of Q-only imaging in the pandemic era. METHODS: Patients who underwent Q-only imaging for pulmonary embolism between March 2020 and February 2021 were analyzed. Patients who underwent lung quantification analysis were excluded. Q-only test results were reported as per modified PIOPED II criteria and single positron emission tomography/computed tomography (SPECT/CT) imaging was performed as needed. Patients were considered concordant or discordant by correlating the Q-only results with CT angiogram (CTA) or clinical diagnosis made through chart review. The diagnostic accuracy was calculated after excluding intermediate probability and nondiagnostic studies. RESULTS: Four hundred and thirty-four patients were identified. One hundred and twenty-eight patients (29.4%) underwent ultrasound Doppler, 37 patients (8.5%) underwent CTA, and 16 patients (3.6%) underwent both. After excluding patients with intermediate probability or nondiagnostic studies and who did not have follow-up (a total of 87 patients [20%]), 347 patients were enrolled in the final analysis. The combined planar and SPECT/CT sensitivity and specificity were 85.4% (72.2%–93.9% confidence interval [CI]) and 98.7% (96.9%–98.6% CI), respectively. The positive predictive value (PPV) of the Q-only imaging was 89.1% (77.3%–95.1% CI) and the negative predictive value (NPV) was 98.2% (96.4%–99% CI). The sensitivity with SPECT/CT reached 100% (CI: 71.5%–100%) with a specificity of 92.3% (CI: 64%–99.8%). The PPV was 85.7% (CI: 62.1%–95.6%) and the NPV was 100%. CONCLUSION: Q-only imaging provides clinically acceptable results. The sensitivity of the Q-only scan is increased when coupled with SPECT/CT.